Abstract
Zogenix, an Emeryville, California–based rare-disease therapy specialist, will pay $250 million to acquire Modis Therapeutics, a start-up focused on rare genetic diseases. Modis’s lead candidate is MT1621, a deoxynucleoside substrate enhancement therapy in late-stage development for the treatment of thymidine kinase 2 deficiency, an often fatal mitochondrial DNA depletion disorder that primarily affects children. Modis was formed in 2016 and raised $30 million in series A funding less than a year ago.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.